Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial …